This page covers how Puma Biotechnology's Operating Margin is calculated and what the current reading is. The metric and its formula are grounded in standardized accounting data. Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Operating Margin
=
Operating Income
Revenue
X
100
=
0.23 %
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors. The Operating Margin value for Puma Biotechnology reflects the latest reported data. The values are grounded in disclosed financial statement line items.
Among Puma Biotechnology's reported metrics, Operating Profit Margin provides a view into a specific part of the financial picture. The most recent reading gains meaning when set against the full distribution of past values.
Operating Profit Margin has shifted lower for Puma Biotechnology in the latest reported period. From 0.16 to 0.16, Puma Biotechnology's Operating Profit Margin shifted 2.08% year over year. The curvature of Puma Biotechnology's Operating Profit Margin trend adds context beyond what the raw numbers convey.
Understanding the fundamental principles of building solid financial models for Puma Biotechnology is extremely important. It helps to project a fair market value of Puma Stock properly, considering its historical fundamentals such as Operating Margin.
Pretax Profit Margin is evolving in line with broader financial reporting trends. Year-ago financials show Puma Biotechnology with Pretax Profit Margin of 0.16.
Puma Biotechnology has a reported Operating Margin of 0.2267%. This reading is 100.65% above the Biotechnology sector and 100.2% above the Health Care industry. Against all United States stocks, Puma Biotechnology's operating margin is 104.11% higher than average.
Fundamental Drivers Relationships
Sector-based pricing multiples position Puma Biotechnology within its competitive valuation range. Mapping the correlation between Puma Biotechnology's fundamental drivers and peer metrics highlights which indicators are most influential for its intrinsic value. More Info.
Puma Biotechnology claims the number one ranking for operating margin among direct rivals. It also claims the number one ranking for return on asset among direct rivals recording roughly 0.48 in Return On Asset for every unit of Operating Margin. Operating Margin outpaces Return On Asset by 2.09 times for Puma Biotechnology. Puma Biotechnology shows Operating Profit Margin decreasing by approximately 2.08% year over year. The most recent annual figure for Operating Profit Margin was 0.16. Valuation multiples such as P/E, P/B, and P/S compare Puma Biotechnology to peer earnings performance.
Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Puma Biotechnology's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to.
Puma Biotechnology is currently under evaluation for operating margin among direct rivals.
Current Valuation Drivers
We derive many important indicators used in calculating different scores of Puma Biotechnology from analyzing Puma Biotechnology's financial statements. These drivers represent accounts that assess Puma Biotechnology's ability to generate profits relative to its revenue, operating costs, and shareholders'.
Puma Biotechnology reports annual revenue of 228.37 M, a profit margin of 13.62%, ROE of 27.97%, debt-to-equity of 5.19. Puma Biotechnology's financial position is often measured through income generation trends and leverage exposure. Profitability indicators are currently positive. Overall market capitalization tier is small-cap. For this reporting period, Puma Biotechnology reflects revenue of 228.37 M, positive EPS of 0.61, operating margin of 22.67%.
Unless otherwise specified, data for Puma Biotechnology is compiled from periodic company reporting and market reference feeds and standardized for comparability. Analyst inputs may be included when coverage is available. Updates may occur throughout the day. Income statement, balance sheet, and cash-flow values follow GAAP or IFRS conventions as reported.